Girentuximab
Alternative Names: Chimeric-monoclonal-antibody-G250; Monoclonal antibody G250; Rencarex; WX-G250Latest Information Update: 05 Nov 2023
At a glance
- Originator Centocor
- Developer Heidelberg Pharma AG
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Immunostimulants; Natural killer cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Suspended Renal cancer